- UK
- How we work
- Optimising the Myeloma Pathway
Optimising the Myeloma Pathway
This collaborative working project between Cardiff and Vale University Hospital Board (CVUHB) and Johnson & Johnson focused on optimising the myeloma treatment pathway. The aim was to alleviate pressure on the Haematology Day Unit at the University Hospital of Wales (UHW) by reconfiguring services to be more efficient, patient-centred and scalable.
J&J has been a proactive partner. Their willingness to engage in innovative projects is invaluable. Partnerships are essential. Public finances alone can’t meet the demand, and pharma’s involvement can accelerate improvements.
Dr Ceri Bygrave, Consultant Haematologist and Myeloma Lead at CVUHB
Background
The Haematology Day Unit at UHW has been operating beyond its capacity, with new patients facing delays in accessing care, often travelling long distances bypassing closer facilities. There was a clear need for a redesigned service model that better meets patient needs and optimises available resources.
Partnership and Solution
Service mapping and gap analysis:
- Both parties are working together to map the current service configuration and identify inefficiencies through workshops and baseline data analysis
Co-creation of a new service model:
- A redesigned pathway is being developed to deliver care more efficiently and closer to home, with a focus on patient needs and workforce optimisation
Collaborative project management:
- Johnson & Johnson provides process expertise and project management support
- CVUHB contributes clinical insight and pathway data to inform the redesign
Implementation and evaluation:
- CVUHB is implementing the new model over a six-month period
- Both parties are measuring success against baseline metrics and plan to publish findings to share best practice